FDA nicotine pouch ruling should prompt Asia Pacific policy rethink

MANILA, Philippines - Rezul -- The Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA) says the U.S. Food and Drug Administration's decision to authorize reduced-risk claims for specific nicotine pouch products should prompt a policy rethink across Asia Pacific.

CAPHRA says too many governments in the region still treat cigarettes, high-risk smokeless tobacco, and smoke-free nicotine products as if they carry the same risk, even though that approach distorts regulation and misleads consumers.

The FDA has authorized nicotine pouch products to be marketed with a specific modified-risk claim stating that using them instead of cigarettes lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.

Nancy Loucas, Executive Coordinator of CAPHRA, said the ruling should be closely studied by regulators across the region.  "This is what risk-proportionate regulation looks like," Loucas said. "The FDA has not said nicotine pouches are harmless. It has recognized that for adults who would otherwise smoke, specific scientifically reviewed products can reduce risk. That is the kind of regulatory honesty many Asia Pacific governments still avoid."

More on Rezul News

• Dream Finders Homes debuts two new model homes at River Hall
• 2026 Independent Guide To Vero Beach New Home Builders
• Discard Junk Removal Named #1 Junk Removal Company in Sacramento Out of 189 Businesses Evaluated
• Foundry Atlas Launches Agency vs. DSCR Cash-Out Refinance Calculator for Real Estate Investors
• J&J Exterminating Mourns the Passing of Founder Bobby John Sr

CAPHRA said this matters especially in South and Southeast Asia, where smokeless tobacco use is already widespread and remains a major health burden.  Prevalence studies in Bangladesh, India, and Myanmar have found smokeless tobacco use is highest among men and in rural communities.

The group said oral nicotine policy therefore cannot be treated as a niche issue. In a region where millions already use oral tobacco, refusing to distinguish between high-risk traditional products and lower-risk modern alternatives is not caution - it is poor public health design. For adults who already use cigarettes or high-risk oral tobacco, access to accurate information and lower-risk alternatives can be the difference between continued exposure and meaningful harm reduction.

CAPHRA said it supports strict youth protections, strong product standards, and tough enforcement against underage sales. But it warned that public health credibility is damaged when governments continue to tolerate cigarettes and entrenched high-risk oral tobacco while refusing to evaluate lower-risk smoke-free alternatives on the basis of relative risk.

More on Rezul News

• Delirious Comedy Club Transforms Into Las Vegas' Newest Live Comedy Studio With Weekly Delirious TV Tapings
• Common Misconceptions About Estate Planning: Why Online Wills May Not Be Enough
• BitTitan Advances MigrationWiz with New Capabilities, Platform Enhancements, and Product Leadership Update
• Sara Abbas Receives "Eniochos" Charioteer Award at 2026 Who is Who International Awards
• Detained at 95: South Korea's Prosecution of a Religious Leader Draws International Alarm

CAPHRA is calling on Asia Pacific governments to review the FDA's findings, regulate oral nicotine products according to evidence and relative risk, enforce strict youth access controls, require robust product standards, and ensure that adults receive accurate information about comparative harms. The group said the test for policymakers is simple: regulate by evidence and relative risk, not by ideology or by treating all nicotine products as interchangeable.

"In a region where oral tobacco use is already widespread, refusing to evaluate lower-risk nicotine alternatives is not precaution, it is a policy choice to leave more dangerous products unchallenged."